

# SCORE Search Results Details for Application 10552515 and Search Result 20080630\_144055\_us-10-552-515-8.rag

<a href="#">Score Home Page</a>	<a href="#">Retrieve Application List</a>	<a href="#">SCORE System Overview</a>	<a href="#">SCORE FAQ</a>	<a href="#">Comments / Suggestions</a>
---------------------------------	---	---------------------------------------	---------------------------	--

This page gives you Search Results detail for the Application 10552515 and Search Result 20080630\_144055\_us-10-552-515-8.rag.

[Go Back to previous page](#)

GenCore version 6.2.1  
Copyright (c) 1993 - 2008 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: June 30, 2008, 17:43:01 ; Search time 71 Seconds  
(without alignments)  
76.429 Million cell updates/sec

Title: US-10-552-515-8

Perfect score: 41

Sequence: 1 ILFEILAKT 9

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 3405708 seqs, 601879884 residues

Total number of hits satisfying chosen parameters: 3405708

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_200711:\*

1: geneseqp1980s:\*

2: geneseqp1990s:\*

3: geneseqp2000:\*

4: geneseqp2001:\*

5: geneseqp2002:\*

6: geneseqp2003a:\*

7: geneseqp2003b:\*

8: geneseqp2004a:\*

```

9:  geneseqp2004b:*
10:  geneseqp2005:*
11:  geneseqp2006:*
12:  geneseqp2007:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

%

Result	Query					Description
No.	Score	Match	Length	DB	ID	
1	41	100.0	9	8	ADT77671	Adt77671 Splice va
2	41	100.0	843	10	AEB13424	Aeb13424 Human pro
3	41	100.0	885	10	AEB13426	Aeb13426 Human pro
4	41	100.0	898	4	ABG15488	Abg15488 Novel hum
5	41	100.0	933	8	ADT77664	Adt77664 Splice va
6	41	100.0	933	11	AEL84788	Ael84788 Tumor mar
7	34	82.9	216	8	AFP84087	Afp84087 Glycine m
8	33	80.5	1053	8	ADJ34836	Adj34836 Xylanase
9	32	78.0	227	7	ABO63675	Abo63675 Klebsiell
10	32	78.0	241	11	AEH61360	Aeh61360 Enterobac
11	32	78.0	458	6	ABU28956	Abu28956 Protein e
12	32	78.0	458	7	ADL46368	Adl46368 UDP-N-ace
13	32	78.0	458	10	AEC10797	Aec10797 Enterococ
14	32	78.0	461	4	AAU35344	Aau35344 Enterococ
15	32	78.0	463	7	ADH86988	Adh86988 Enterococ
16	32	78.0	463	12	AJF28249	Ajf28249 Enterococ
17	32	78.0	526	4	AAB96073	Aab96073 Putative
18	32	78.0	678	7	ABO71947	Abo71947 Pseudomon
19	32	78.0	1059	8	AFQ00574	Afq00574 Glycine m
20	32	78.0	1076	10	AEN23392	Aen23392 Dugesia j
21	32	78.0	1143	8	AFQ00575	Afq00575 Glycine m
22	31	75.6	151	8	ADT56971	Adt56971 Plant pol
23	31	75.6	166	8	ADK16481	Adk16481 Nanoarcha
24	31	75.6	370	5	ABB90367	Abb90367 Human pol
25	31	75.6	370	7	ADN95748	Adn95748 Human BEC
26	31	75.6	370	8	ADO19268	Ado19268 Human PRO
27	31	75.6	370	8	ADQ19215	Adq19215 Human sof
28	31	75.6	620	8	ADL05423	Adl05423 M. catarr
29	31	75.6	1062	8	ADN19023	Adn19023 Bacterial
30	31	75.6	1102	10	AEN27462	Aen27462 Nostoc pu
31	30	73.2	93	9	AFQ75635	Afq75635 Glycine m
32	30	73.2	239	7	ADF07117	Adf07117 Bacterial
33	30	73.2	292	6	ABU35185	Abu35185 Protein e
34	30	73.2	302	11	AFC64090	Afc64090 Maize ami
35	30	73.2	303	5	ABR52340	Abr52340 Protein r

36	30	73.2	304	8	ADL04486	Adl04486 M. catarr
37	30	73.2	320	11	AFC64089	Afc64089 Maize ami
38	30	73.2	322	5	ABB54400	Abb54400 Lactococc
39	30	73.2	345	10	AEN35225	Aen35225 Zea mays
40	30	73.2	345	11	AFC64088	Afc64088 Maize ami
41	30	73.2	361	9	AFQ22375	Afq22375 Glycine m
42	30	73.2	363	5	ABB91326	Abb91326 Herbicida
43	30	73.2	364	3	AAB18932	Aab18932 Amino aci
44	30	73.2	364	12	AGA87456	Aga87456 Tobacco c
45	30	73.2	365	2	AAR34765	Aar34765 OMTIII tr

## ALIGNMENTS

## RESULT 1

ADT77671

ID ADT77671 standard; peptide; 9 AA.

XX

AC ADT77671;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human; prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH ) US DEPT HEALTH &amp; HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or encoding nucleic acid molecule for diagnosing, preventing or treating cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 8; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope is predicted to bind HLA2-01 and was identified using an HLA binding motif program. It corresponds to amino acids 258-266 of SV-NGEP.

CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino acids of SV-NGEP which specifically bind to an antibody that specifically binds a polypeptide comprising amino acids 157-933 of SV-NGEP are claimed. The invention provides methods for: detecting prostate cancer in a subject by contacting a sample with an antibody that specifically binds a SV-NGEP polypeptide and detecting the formation of an immune complex, or detecting an increase in expression of SV-NGEP polypeptide or mRNA; producing an immune response against a cell expressing SV-NGEP, for example in a subject with prostate cancer, by administering SV-NGEP polypeptide or polynucleotide to produce an immune response that decreases growth of the prostate cancer; inhibiting the growth of a malignant cell that expresses SV-NGEP by culturing cytotoxic T lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting these with the malignant cell; and inhibiting the growth of a malignant cell by contact with an antibody that specifically binds SV-NGEP, where the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match 100.0%; Score 41; DB 8; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 2.9e+06;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 ILFEILAKT 9

|||||||

Db

1 ILFEILAKT 9

RESULT 2

AEB13424

ID AEB13424 standard; protein; 843 AA.

XX

AC AEB13424;

XX

DT 22-SEP-2005 (first entry)

XX

DE Human prostate specific polypeptide #1.

XX

KW Screening; diagnosis; drug delivery; prostate specific polypeptide; cancer; prostate tumor; cytostatic; neoplasm.

XX

OS Homo sapiens.

XX

PN WO2005062788-A2.

XX  
PD 14-JUL-2005.  
XX  
PF 16-DEC-2004; 2004WO-US042406.  
XX  
PR 22-DEC-2003; 2003US-0531809P.  
XX  
PA (AVAL-) AVALON PHARM INC.  
XX  
PI Weigle B, Ebner R;  
XX  
DR WPI; 2005-497793/50.  
DR N-PSDB; AEB13423.  
XX  
PT Novel isolated prostate specific polypeptide, useful for treating cancer,  
PT and identifying agent that modulates activity of cancer related gene.  
XX  
PS Claim 12; SEQ ID NO 3; 59pp; English.  
XX  
CC The invention relates to an isolated prostate specific polypeptide  
CC comprising one or more immunogenic fragments. The invention also relates  
CC to a method of identifying an agent that modulates the activity of a  
CC cancer related gene involving contacting a compound with a cell  
CC containing a gene under conditions promoting the expression of the gene,  
CC detecting a difference in expression of the gene relative to when the  
CC compound is not present and identifying an agent that modulates the  
CC activity of a cancer related gene, a method of identifying an anti-  
CC neoplastic agent involving contacting a cell exhibiting neoplastic  
CC activity with a compound first identified as a cancer related gene  
CC modulator using and determining a decrease in neoplastic activity after  
CC contacting, when compared to when the contacting does not occur, or  
CC administering an agent first identified to an animal exhibiting a cancer  
CC condition and detecting a decrease in cancerous condition, a method of  
CC determining the cancerous status of a cell involving determining an  
CC increase in the level of expression in a cell of a gene where an elevated  
CC expression relative to a known non-cancerous cell indicates a cancerous  
CC state or potentially cancerous state, an antibody that reacts with a  
CC prostate specific polypeptide, an immunoconjugate comprising the antibody  
CC and a cytotoxic agent, a method of treating cancer involving contacting a  
CC cancerous cell in vivo with an agent having activity against a prostate  
CC specific polypeptide and an immunogenic composition the prostate specific  
CC polypeptide. The prostate specific polypeptide is useful for identifying  
CC an agent that modulates the activity of a cancer related gene. The  
CC immunogenic composition is useful for treating cancer, preferably  
CC prostate cancer in an animal, e.g. human, which involves administering  
CC the immunogenic composition that is sufficient to elicit the production  
CC of cytotoxic T lymphocytes specific for the prostate specific  
CC polypeptide. The invention is useful for identifying anti-neoplastic  
CC agents. This sequence represents a human prostate specific polypeptide of

CC the invention.

XX

SQ Sequence 843 AA;

Query Match 100.0%; Score 41; DB 10; Length 843;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9

|||||||

Db 259 ILFEILAKT 267

RESULT 3

AEB13426

ID AEB13426 standard; protein; 885 AA.

XX

AC AEB13426;

XX

DT 22-SEP-2005 (first entry)

XX

DE Human prostate specific polypeptide #2.

XX

KW Screening; diagnosis; drug delivery; prostate specific polypeptide;

KW cancer; prostate tumor; cytostatic; neoplasm.

XX

OS Homo sapiens.

XX

PN WO2005062788-A2.

XX

PD 14-JUL-2005.

XX

PF 16-DEC-2004; 2004WO-US042406.

XX

PR 22-DEC-2003; 2003US-0531809P.

XX

PA (AVAL-) AVALON PHARM INC.

XX

PI Weigle B, Ebner R;

XX

DR WPI; 2005-497793/50.

DR N-PSDB; AEB13425.

XX

PT Novel isolated prostate specific polypeptide, useful for treating cancer,  
PT and identifying agent that modulates activity of cancer related gene.

XX

PS Claim 12; SEQ ID NO 5; 59pp; English.

XX

CC The invention relates to an isolated prostate specific polypeptide

CC comprising one or more immunogenic fragments. The invention also relates to a method of identifying an agent that modulates the activity of a cancer related gene involving contacting a compound with a cell containing a gene under conditions promoting the expression of the gene, detecting a difference in expression of the gene relative to when the compound is not present and identifying an agent that modulates the activity of a cancer related gene, a method of identifying an anti-neoplastic agent involving contacting a cell exhibiting neoplastic activity with a compound first identified as a cancer related gene modulator using and determining a decrease in neoplastic activity after contacting, when compared to when the contacting does not occur, or administering an agent first identified to an animal exhibiting a cancer condition and detecting a decrease in cancerous condition, a method of determining the cancerous status of a cell involving determining an increase in the level of expression in a cell of a gene where an elevated expression relative to a known non-cancerous cell indicates a cancerous state or potentially cancerous state, an antibody that reacts with a prostate specific polypeptide, an immunoconjugate comprising the antibody and a cytotoxic agent, a method of treating cancer involving contacting a cancerous cell in vivo with an agent having activity against a prostate specific polypeptide and an immunogenic composition the prostate specific polypeptide. The prostate specific polypeptide is useful for identifying an agent that modulates the activity of a cancer related gene. The immunogenic composition is useful for treating cancer, preferably prostate cancer in an animal, e.g. human, which involves administering the immunogenic composition that is sufficient to elicit the production of cytotoxic T lymphocytes specific for the prostate specific polypeptide. The invention is useful for identifying anti-neoplastic agents. This sequence represents a human prostate specific polypeptide of the invention.

XX

SQ Sequence 885 AA;

Query Match 100.0%; Score 41; DB 10; Length 885;  
 Best Local Similarity 100.0%; Pred. No. 14;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 ILFEILAKT 9  
 |||||||||

Db

259 ILFEILAKT 267

RESULT 4

ABG15488

ID ABG15488 standard; protein; 898 AA.

XX

AC ABG15488;

XX

DT 18-FEB-2002 (first entry)

XX  
DE Novel human diagnostic protein #15479.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
DR N-PSDB; AAS79675.  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 45847; 103pp; English.  
XX  
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this

CC patent did not appear in the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 898 AA;

Query Match 100.0%; Score 41; DB 4; Length 898;  
 Best Local Similarity 100.0%; Pred. No. 14;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9  
 |||||||||  
 Db 351 ILFEILAKT 359

RESULT 5

ADT77664

ID ADT77664 standard; protein; 933 AA.

XX

AC ADT77664;

XX

DT 15-JUN-2007 (revised)

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) polypeptide.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;

KW prostate cancer; cytostatic; gene therapy; immunotherapy; BOND\_PC;

KW NGEP long variant; NGEP long variant [Homo sapiens]; GO5886.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Domain 1. .345

FT /label= Cytoplasmic

FT Region 157. .933

FT /note= "An immunogenic fragment comprising 8 consecutive amino acids that specifically binds to an antibody that specifically binds to a polypeptide comprising amino acids 157-933 is referred to in Claim 1"

FT Region 170. .178

FT /note= "Epitope, predicted to bind HLA2-01"

FT Region 215. .223

FT /note= "Epitope, predicted to bind HLA2-01"

FT Region 258. .266

FT /note= "Epitope, predicted to bind HLA2-01"

FT Domain 346. .368

FT /label= Transmembrane

FT Domain 369. .421

FT /label= External  
FT /note= "Cell surface"  
FT Region 403. .411  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Domain 422. .441  
FT /label= Transmembrane  
FT Region 427. .435  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Domain 442. .501  
FT /label= Cytoplasmic  
FT Domain 502. .524  
FT /label= Transmembrane  
FT Domain 525. .543  
FT /label= External  
FT /note= "Cell surface"  
FT Domain 544. .566  
FT /label= Transmembrane  
FT Region 557. .565  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Region 562. .570  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Domain 567. .586  
FT /label= Cytoplasmic  
FT Domain 587. .609  
FT /label= Transmembrane  
FT Domain 610. .714  
FT /label= External  
FT /note= "Cell surface"  
FT Domain 715. .737  
FT /label= Transmembrane  
FT Domain 738. .761  
FT /label= Cytoplasmic  
FT Domain 762. .784  
FT /label= Transmembrane  
FT Domain 785. .933  
FT /label= External  
FT /note= "Cell surface"  
FT Region 846. .854  
FT /note= "Epitope, predicted to bind HLA2-01"  
XX  
PN WO2004092213-A1.  
XX  
PD 28-OCT-2004.  
XX  
PF 05-APR-2004; 2004WO-US010588.  
XX  
PR 08-APR-2003; 2003US-0461399P.  
XX  
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

DR N-PSDB; ADT77665.

DR PC:NCBI; gi48093524.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or  
PT encoding nucleic acid molecule for diagnosing, preventing or treating  
PT cancer, especially prostate cancer.

XX

PS Claim 1; SEQ ID NO 1; 88pp; English.

XX

CC The present sequence is the protein sequence of splice variant-novel gene  
CC expressed in prostate (SV-NGEP). SV-NGEP is identical to NGEF from amino  
CC acid 1-157, diverging from amino acid 158. Expression analysis in 76  
CC normal and foetal tissues showed SV-NGEP to be strongly expressed only in  
CC a prostate sample. Claimed methods for detecting prostate cancer in a  
CC subject comprise: contacting the sample with an antibody that  
CC specifically binds a SV-NGEP polypeptide and detecting the formation of  
CC an immune complex; or detecting an increase in expression of SV-NGEP  
CC polypeptide or mRNA. Antibodies to an SV-NGEP polypeptide can be used to  
CC detect metastatic prostate cancer cells at locations other than the  
CC prostate. A claimed method for producing an immune response against a  
CC cell expressing SV-NGEP, for example in a subject with prostate cancer,  
CC comprises administering the polypeptide, or a polynucleotide encoding it,  
CC to produce an immune response that decreases growth of the prostate  
CC cancer. A claimed method for inhibiting the growth of a malignant cell  
CC that expresses SV-NGEP comprises culturing cytotoxic T lymphocytes (CTLs)  
CC with SV-NGEP to produce activated CTLs that recognise an NGEF expressing  
CC cell, and contacting the malignant cell with the activated CTLs.  
CC Alternatively, growth of a malignant cell is inhibited by contact with an  
CC antibody that specifically binds an SV-NGEP polypeptide, where the  
CC antibody is linked to an effector molecule (chemotherapeutic agent or  
CC toxin) that inhibits growth of the malignant cell. This may be performed  
CC in vivo. Kits for detecting an SV-NGEP polypeptide or polynucleotide in a  
CC sample are also claimed.

CC

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
CC information from BOND.

XX

SQ Sequence 933 AA;

Query Match 100.0%; Score 41; DB 8; Length 933;  
 Best Local Similarity 100.0%; Pred. No. 14;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 ILFEILAKT 9  
|||||||

Db 258 ILFEILAKT 266

RESULT 6

AEL84788

ID AEL84788 standard; protein; 933 AA.

XX

AC AEL84788;

XX

DT 18-OCT-2007 (revised)

DT 15-JUN-2007 (revised)

DT 28-DEC-2006 (first entry)

XX

DE Tumor marker gene NGEP SEQ ID NO 155.

XX

KW cytostatic; diagnosis; prognosis; tumor marker; gene expression;  
KW drug screening; cancer; neoplasm; NGEP; BOND\_PC; NGEP long variant;  
KW GO5886.

XX

OS Homo sapiens.

XX

PN WO2006110593-A2.

XX

PD 19-OCT-2006.

XX

PF 07-APR-2006; 2006WO-US013172.

XX

PR 07-APR-2005; 2005US-0669342P.

PR 11-OCT-2005; 2005US-0725982P.

XX

PA (MACR-) MACROGENICS INC.

XX

PI Von Haller PD, Schummer M, Meyer DW, Schubert LA, Tjoelker LW;

XX

DR WPI; 2006-814687/82.

DR N-PSDB; AEL84787.

DR REFSEQ; NP\_001001891.

DR PC:NCBI; gi48093524.

XX

PT Detecting or diagnosing cancer in a subject comprises determining  
PT expression of at least one gene, and comparing level of expression to a  
PT control sample from a normal subject, where increased expression level  
PT indicates cancer.

XX

PS Claim 8; SEQ ID NO 155; 583pp; English.

XX

CC The invention describes a method of detecting or diagnosing cancer in a  
CC subject comprising determining the expression level of at least one gene,  
CC and comparing the level of expression to a corresponding control sample

CC from a normal subject, where cancer is detected or diagnosed if there is  
 CC an increase in the expression level of the gene relative to the  
 CC expression in the control sample. Also described are: identifying a  
 CC compound to be tested for its ability to prevent, treat, manage, or  
 CC ameliorate cancer or its symptom; a compound identified by the method;  
 CC treating cancer in a patient; treating a cancer in a subject that is  
 CC fully or partially refractory to a first treatment in a patient; and a  
 CC pharmaceutical composition comprising an amount of an antibody selected  
 CC from anti-SLC12A2, anti-FLJ23375, anti-GRM5, anti-TAS2R1, anti-NRXN2,  
 CC anti-C14orf160, anti-MGC 15668, anti-MGC33486, anti-TMEM16F, anti-FAT,  
 CC anti-KIAA0195, anti-LRFN, anti-NFASC, anti-BAT2D1, anti-MGC2963, anti-  
 CC KIAA0685, anti-EDG3, anti-GGTL3, anti-PLVAP, anti-FLJ31528, anti-  
 CC FLJ90709, anti-VEZATIN, anti-TMPRSS9, anti-ATP13A5, anti-PKHD1L1, anti-  
 CC C2orf18, anti-ANKRD22, anti-FAM62B, anti-LOC57168, anti-CDKAL1, anti-  
 CC SLC39A3v1, anti-SLC39A3v2, anti-BAT5, anti-TM9SF4, anti-DC2, anti-VAPB,  
 CC anti-XTP3TPB, anti-TACSTD2, anti-FNDC3A, anti-GK001, anti-OCIAD2, anti-  
 CC PR01855, anti-C20orf3, anti-SDFR1, anti-FLJ20481, anti-LENG4, anti-  
 CC FLJ12443, anti-ARP5 Long, anti-ARP5 Short, anti-TMD0645, anti-NGEP, anti-  
 CC IL1RAP1, anti-PLXNB1, anti-ATP2B2, anti~FLJ11848, anti-ENTPD2, anti-  
 CC PPM1H, anti-KRTKAP3, anti-KCNC3, anti-TM9SF1, anti-ULBP1, anti-C19orf26,  
 CC anti-KIAA830, anti-KIAA1244, anti-KIAA1797, anti-MGC26856, anti-NETO2,  
 CC anti-SUSD2, anti-FOLR2, anti-EMR2, ENTPD1, anti-ATP10B, anti-PTK7, anti-  
 CC FLJ14681, anti-C20orf22, anti-FLJ14281, anti-FAM8A1, anti-TMED7, anti-  
 CC C20orf108, anti-ATAD1, anti-GPR154, anti-C14orf27, anti-OSAP, anti-  
 CC FAD104, anti-FLJ90492, anti-SLC27A3, anti-RON, anti-ATP13A1, anti-  
 CC DKFZP564D166, anti-ESSPL, anti-EXTL3, anti-KAI1, anti-KIAA0960, anti-  
 CC MTRNL, anti-SLC27A1, anti-GRIA, anti-OR4M1, anti-KIAA1679, or anti-UPK-1b  
 CC antibody, and a pharmaceutical carrier. The methods are useful for  
 CC detecting, diagnosing, and treating cancer, e.g. colon, lung, ovary,  
 CC prostate, pancreas, or bladder cancer. This is the amino acid sequence of  
 CC NGEP, altered levels of expression are useful in the diagnosis or  
 CC prognosis of cancer.

CC Revised record issued on 18-OCT-2007 : Enhanced with precomputed  
 CC information from BOND.

XX

SQ Sequence 933 AA;

Query Match 100.0%; Score 41; DB 11; Length 933;  
 Best Local Similarity 100.0%; Pred. No. 14;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9  
 |||||||||  
 Db 258 ILFEILAKT 266

RESULT 7  
 AFP84087

ID AFP84087 standard; protein; 216 AA.

XX

AC AFP84087;

XX

DT 18-OCT-2007 (first entry)

XX

DE Glycine max protein SEQ ID NO:175265.

XX

KW plant; cold tolerance; heat tolerance; drought resistance;

KW herbicide resistance; pathogen resistance; pesticide resistance;

KW disease-resistance; crop improvement; insect resistance;

KW nitrogen fixation; plant growth regulation; plant disease;

KW stress tolerance; seed oil; transgenic.

XX

OS Glycine max.

XX

PN US2004031072-A1.

XX

PD 12-FEB-2004.

XX

PF 28-APR-2003; 2003US-00424599.

XX

PR 06-MAY-1999; 99US-00304517.

PR 05-NOV-2001; 2001US-00985678.

XX

PA (LROS/) LA ROSA T J.

PA (ZHOUE/) ZHOU Y.

PA (KOVA/) KOVALIC D K.

PA (CAOY/) CAO Y.

XX

PI La Rosa TJ, Zhou Y, Kovalic DK, Cao Y;

XX

DR WPI; 2004-168999/16.

XX

PT New recombinant DNA construct, useful in producing plants with desired

PT properties, e.g. increased cold, heat or drought tolerance or tolerance

PT to herbicides, extreme osmotic conditions or pathogens and improved plant

PT growth and development.

XX

PS Claim 2; SEQ ID NO 175265; 15pp; English.

XX

CC The invention relates to a recombinant DNA construct, polynucleotides or

CC polypeptides which are useful in improving plant cold, heat or drought

CC tolerance or tolerance to herbicides, extreme osmotic conditions,

CC pathogens or pests, in improving yield by modification of photosynthesis

CC or of carbohydrate, nitrogen or phosphorus use and/or uptake, in

CC manipulating growth rate in plant cells by modification of the cell cycle

CC pathway, in providing increased resistance to plant disease and improved

CC plant growth and development under at least one stress condition, in

CC producing galactomannan, plant growth regulators and lignin, in  
CC increasing the rate of homologous recombination in plants, in modifying  
CC seed oil yield and/or content and seed protein yield and/or content and  
CC in encoding a plant transcription factor. The present sequence represents  
CC a Glycine max protein of the invention. Note: This sequence is not shown  
CC in the specification but was obtained in electronic format directly from  
CC USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 216 AA;

Query Match 82.9%; Score 34; DB 8; Length 216;  
Best Local Similarity 87.5%; Pred. No. 90;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy

1 ILFEILAK 8  
||||:|||

Db

129 ILFELLAK 136

RESULT 8

ADJ34836

ID ADJ34836 standard; protein; 1053 AA.

XX

AC ADJ34836;

XX

DT 22-APR-2004 (first entry)

XX

DE Xylanase from an environmental sample seq id 52.

XX

KW antibacterial; fungicide; thermostable xylanase activity;  
KW dough conditioning; beverage production; nutritional supplement;  
KW animal feed; lignin reduction; wood product; xylan; bacterial infection;  
KW fungal infection; coccidiosis.

XX

OS Unidentified.

XX

PN WO2003106654-A2.

XX

PD 24-DEC-2003.

XX

PF 16-JUN-2003; 2003WO-US019153.

XX

PR 14-JUN-2002; 2002US-0389299P.

XX

PA (DIVE-) DIVERSA CORP.

XX

PI Steer B, Callen W, Healey S, Hazlewood G, Wu D, Blum D;

PI Esteghlalian A;

XX

DR WPI; 2004-099016/10.

DR N-PSDB; ADJ34835.

XX

PT Novel xylanase recombinant polypeptide useful for improving textile texture, treating paper, eliminating microorganisms.

XX

PS Claim 60; SEQ ID NO 52; 570pp; English.

XX

CC The invention describes an isolated or recombinant polypeptide (I),  
CC having 50% or more identity to 190 300-1200 residue amino acid sequences  
CC (S1), given in the specification, over a region of 100 or more residues  
CC and the polypeptide as thermostable xylanase activity. (I) is useful for:  
CC dough conditioning; beverage production; as a nutritional supplement in  
CC animal feed; reducing lignin in a wood or a wood product; and for  
CC eliminating and protecting animals from a microorganism comprising xylan.  
CC The polynucleotide (II) encoding (I) is useful for amplifying nucleic  
CC acid encoding a polypeptide having a xylanase activity which involves  
CC amplification of a template nucleic acid with a primer pair capable of  
CC amplifying (II) or its subsequence. (I) is useful for treating and  
CC preventing bacterial infection and fungal infection e.g. coccidiosis.  
CC This is the amino acid sequence of a xylanase protein isolated from an  
CC environmental sample.

XX

SQ Sequence 1053 AA;

Query Match 80.5%; Score 33; DB 8; Length 1053;  
Best Local Similarity 75.0%; Pred. No. 8.1e+02;  
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9

||||:|||:

Db 124 LFEVLART 131

RESULT 9

AB063675

ID AB063675 standard; protein; 227 AA.

XX

AC AB063675;

XX

DT 29-JUL-2004 (first entry)

XX

DE Klebsiella pneumoniae polypeptide seqid 10192.

XX

KW Recombinant expression vector; transcription regulatory element;

KW Klebsiella pneumoniae protein; antibacterial; Vaccine.

XX

OS Klebsiella pneumoniae.

XX

PN US6610836-B1.  
XX  
PD 26-AUG-2003.  
XX  
PF 27-JAN-2000; 2000US-00489039.  
XX  
PR 29-JAN-1999; 99US-0117747P.  
XX  
PA (GENO-) GENOME THERAPEUTICS CORP.  
XX  
PI Breton GL, Osborne M;  
XX  
DR WPI; 2003-895346/82.  
DR N-PSDB; ACH97226.  
XX  
PT New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for  
PT preparing a vaccine composition against Klebsiella pneumoniae.  
XX  
PS Disclosure; SEQ ID NO 10192; 932pp; English.  
XX  
CC The invention describes a new isolated nucleic acid encoding a Klebsiella  
CC pneumoniae polypeptide. Also described are: a recombinant expression  
CC vector comprising the nucleic acid, operably linked to a transcription  
CC regulatory element; and a cell comprising the recombinant expression  
CC vector. The nucleic acid is useful for preparing a vaccine composition  
CC against Klebsiella pneumoniae. This is the amino acid sequence of a  
CC Klebsiella pneumoniae polypeptide of the invention  
XX  
SQ Sequence 227 AA;

Query Match 78.0%; Score 32; DB 7; Length 227;  
Best Local Similarity 87.5%; Pred. No. 2.5e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
|| |||||  
Db 58 LFSILAKT 65

RESULT 10  
AEH61360  
ID AEH61360 standard; protein; 241 AA.  
XX  
AC AEH61360;  
XX  
DT 13-JUL-2006 (first entry)  
XX  
DE Enterobacter cloacae protein amino acid sequence - SEQ ID 7797.  
XX

KW diagnosis; vaccine; bacterial infection; enterobacter infection;  
KW antibacterial; screening.  
XX  
OS Enterobacter cloacae.  
XX  
PN US7041814-B1.  
XX  
PD 09-MAY-2006.  
XX  
PF 18-FEB-1999; 99US-00252691.  
XX  
PR 18-FEB-1998; 98US-0074787P.  
PR 24-JUL-1998; 98US-0094145P.  
XX  
PA (GENO-) GENOME THERAPEUTICS CORP.  
XX  
PI Weinstock KG, Deloughery C, Bush D;  
XX  
DR WPI; 2006-349670/36.  
DR N-PSDB; AEH53965.  
XX  
PT New nucleic acid encoding an Enterobacter cloacae polypeptide, useful for  
PT detecting, preventing, and treating pathological conditions resulting  
PT from bacterial infections.  
XX  
PS Disclosure; SEQ ID NO 7797; 165pp; English.  
XX  
CC The invention comprises the amino acid and coding sequences of  
CC Enterobacter cloacae proteins. The DNA and protein sequences of the  
CC invention are useful for detecting, preventing, and treating pathological  
CC conditions resulting from bacterial infections, and as components of  
CC antibacterial vaccines. The DNA and protein sequences of the invention  
CC are also useful in screening for compounds which interfere with the  
CC Enterobacter cloacae life cycle or inhibit infection. The present amino  
CC acid sequence represents an Enterobacter cloacae protein of the  
CC invention.  
XX  
SQ Sequence 241 AA;

Query Match 78.0%; Score 32; DB 11; Length 241;  
Best Local Similarity 87.5%; Pred. No. 2.7e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
|| |||||  
Db 72 LFSILAKT 79

RESULT 11

ABU28956

ID ABU28956 standard; protein; 458 AA.

XX

AC ABU28956;

XX

DT 15-JUN-2007 (revised)

DT 19-JUN-2003 (first entry)

XX

DE Protein encoded by Prokaryotic essential gene #14483.

XX

KW Antisense; prokaryotic essential gene; cell proliferation; drug design;

KW BOND\_PC; UDP-N-acetylglucosamine pyrophosphorylase;

KW UDP-N-acetylglucosamine pyrophosphorylase [Enterococcus faecalis V583];

KW glmU.

XX

OS Enterococcus faecalis.

XX

PN WO200277183-A2.

XX

PD 03-OCT-2002.

XX

PF 21-MAR-2002; 2002WO-US009107.

XX

PR 21-MAR-2001; 2001US-00815242.

PR 06-SEP-2001; 2001US-00948993.

PR 25-OCT-2001; 2001US-0342923P.

PR 08-FEB-2002; 2002US-00072851.

PR 06-MAR-2002; 2002US-0362699P.

XX

PA (ELIT-) ELITRA PHARM INC.

XX

PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;

PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;

XX

DR WPI; 2003-029926/02.

DR N-PSDB; ACA32826.

DR PC:NCBI; gi29342175.

DR PC:SWISSPROT; Q839U1.

XX

PT New antisense nucleic acids, useful for identifying proteins or screening  
PT for homologous nucleic acids required for cellular proliferation to  
PT isolate candidate molecules for rational drug discovery programs.

XX

PS Claim 25; SEQ ID NO 56880; 1766pp; English.

XX

CC The invention relates to an isolated nucleic acid comprising any one of  
CC the 6213 antisense sequences given in the specification where expression  
CC of the nucleic acid inhibits proliferation of a cell. Also included are:  
CC (1) a vector comprising a promoter operably linked to the nucleic acid

CC encoding a polypeptide whose expression is inhibited by the antisense nucleic acid; (2) a host cell containing the vector; (3) an isolated polypeptide or its fragment whose expression is inhibited by the antisense nucleic acid; (4) an antibody capable of specifically binding the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular proliferation or the activity of a gene in an operon required for proliferation; (7) identifying a compound that influences the activity of the gene product or that has an activity against a biological pathway required for proliferation, or that inhibits cellular proliferation; (8) identifying a gene required for cellular proliferation or the biological pathway in which a proliferation-required gene or its gene product lies or a gene on which the test compound that inhibits proliferation of an organism acts; (9) manufacturing an antibiotic; (10) profiling a compound's activity; (11) a culture comprising strains in which the gene product is overexpressed or underexpressed; (12) determining the extent to which each of the strains is present in a culture or collection of strains; or (13) identifying the target of a compound that inhibits the proliferation of an organism. The antisense nucleic acids are useful for identifying proteins or screening for homologous nucleic acids required for cellular proliferation to isolate candidate molecules for rational drug discovery programs, or for screening homologous nucleic acids required for proliferation in cells other than *S. aureus*, *S. typhimurium*, *K. pneumoniae* or *P. aeruginosa*. The present sequence is encoded by one of the target prokaryotic essential genes. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at [ftp://wipo.int/pub/published\\_pct\\_sequences](ftp://wipo.int/pub/published_pct_sequences)

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
CC information from BOND.

XX

SQ Sequence 458 AA;

Query Match 78.0%; Score 32; DB 6; Length 458;  
Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
||| ||||  
Db 181 LFEALAKT 188

RESULT 12

ADL46368

ID ADL46368 standard; protein; 458 AA.

XX

AC ADL46368;

XX

DT 20-MAY-2004 (first entry)

XX  
DE UDP-N-acetylpyruvoylglucosamine reductase protein #1.  
XX  
KW antibacterial; UDP-N-acetylglucosamine 1-carboxyvinyl transferase-1;  
KW CTP: CMP-3-deoxy-D-manno-octulosonate transferase;  
KW UDP-N-acetylmuramylalanyl-D-glutamate-2-6-diaminopimelate ligase;  
KW D-alanine-D-alanine adding enzyme; D-alanine-D-alanine ligase;  
KW UDP-N-acetylpyruvoylglucosamine reductase;  
KW UDP-N-acetylglucosamine pyrophosphorylase;  
KW UDP-N-acetylmuramoylalanine-D-glutamate ligase;  
KW DP-N-acetylmuramate:alanine ligase; aspartate semialdehyde dehydrogenase;  
KW UDP-N-acetylmuramoylalanyl-D-glutamate; X-ray diffraction analysis;  
KW enzyme.  
XX  
OS Pseudomonas aeruginosa.  
XX  
PN WO2003087353-A2.  
XX  
PD 23-OCT-2003.  
XX  
PF 08-APR-2003; 2003WO-CA000481.  
XX  
PR 08-APR-2002; 2002US-0370899P.  
PR 08-APR-2002; 2002US-0370915P.  
PR 09-APR-2002; 2002US-0371107P.  
PR 09-APR-2002; 2002US-0371185P.  
PR 31-MAY-2002; 2002US-0385426P.  
PR 06-JUN-2002; 2002US-0386283P.  
PR 01-AUG-2002; 2002US-0400348P.  
PR 06-NOV-2002; 2002US-0424395P.  
PR 08-NOV-2002; 2002US-0425200P.  
PR 24-DEC-2002; 2002US-0436345P.  
PR 24-DEC-2002; 2002US-0436349P.  
PR 26-DEC-2002; 2002US-0436568P.  
PR 27-DEC-2002; 2002US-0436675P.  
PR 27-DEC-2002; 2002US-0436734P.  
PR 27-DEC-2002; 2002US-0436885P.  
PR 27-DEC-2002; 2002US-0436889P.  
PR 27-DEC-2002; 2002US-0436893P.  
PR 27-DEC-2002; 2002US-0436900P.  
PR 30-DEC-2002; 2002US-0437013P.  
XX  
PA (AFFI-) AFFINUM PHARM INC.  
XX  
PI Edwards A, Dharamsi A, Vedadi M, Domagala M, Houston S, Awrey D;  
PI Beattie B, Mansoury K, Ouyang H, Vallee F, Richards D, Nethery K;  
PI Virag C, Buzadzija K, Pinder B, Alam MZ, Tai M, Canadien V;  
PI Kanagarajah D, Thalakada R;  
XX

DR WPI; 2003-865361/80.

DR N-PSDB; ADL46367.

XX

PT New recombinant bacterial enzymes involved in cell membrane biogenesis,  
PT useful for designing potential antibacterial agents.

XX

PS Claim 245; SEQ ID NO 86; 407pp; English.

XX

CC The invention relates to isolated, recombinant polypeptides (I) that have  
CC at least one activity of specified bacterial enzymes involved in cell  
CC membrane biogenesis. (I) are: UDP-N-acetylglucosamine 1-carboxyvinyl  
CC transferase-1 of Streptococcus pneumoniae (S.p), Pseudomonas aeruginosa  
CC (P.a.) or Staphylococcus aureus (S.a.); CTP: CMP-3-deoxy-D-manno-  
CC octulosonate transferase of Escherichia coli (E.c.) or Haemophilus  
CC influenzae (H.i.); UDP-N-acetylmuramylalanyl-D-glutamate- 2,6-  
CC diaminopimelate ligase of P.a.; D-alanine:D-alanine adding enzyme of S.a.  
CC or P.a.; D-alanine-D-alanine ligase of Enterococcus faecalis (E.f.); UDP-N-  
CC -acetylpuyruvoylglucosamine reductase of P.a. or H.i.; UDP-N-  
CC acetylglucosamine pyrophosphorylase of E.f., H.i. or S.a.; UDP-N-  
CC acetylmuramoylalanine-D-glutamate ligase of E.f. or H.i.; DP-N-  
CC acetylmuramate:alanine ligase of E.c.; and aspartate semialdehyde  
CC dehydrogenase of H.i and UDP-N-acetylmuramoylalanyl-D-glutamate (sic) of  
CC H.i. Crystalline (I) are used to determine (by X-ray diffraction  
CC analysis) the structural coordinates of (I), and these then used to  
CC design modulators of (I), potential therapeutic agents for treating  
CC diseases caused by the specified bacteria. This sequence represents a  
CC protein of the invention.

XX

SQ Sequence 458 AA;

Query Match 78.0%; Score 32; DB 7; Length 458;  
 Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9

|||||||

Db 181 LFEALAKT 188

RESULT 13

AEC10797

ID AEC10797 standard; protein; 458 AA.

XX

AC AEC10797;

XX

DT 20-OCT-2005 (first entry)

XX

DE Enterococcus faecalis GLMU protein.

XX

KW protein purification; antibacterial; antimicrobial; infection;  
KW drug screening; UDP-N-acetylglucosamine pyrophosphorylase.  
XX  
OS Enterococcus faecalis.  
XX  
PN US2005181388-A1.  
XX  
PD 18-AUG-2005.  
XX  
PF 04-OCT-2004; 2004US-00958216.  
XX  
PR 02-APR-2002; 2002US-0369511P.  
PR 04-APR-2002; 2002US-0369817P.  
PR 04-APR-2002; 2002US-0370102P.  
PR 08-APR-2002; 2002US-0370778P.  
PR 08-APR-2002; 2002US-0370792P.  
PR 08-APR-2002; 2002US-0370820P.  
PR 08-APR-2002; 2002US-0370859P.  
PR 08-APR-2002; 2002US-0370899P.  
PR 08-APR-2002; 2002US-0370915P.  
PR 09-APR-2002; 2002US-0371067P.  
PR 09-APR-2002; 2002US-0371107P.  
PR 09-APR-2002; 2002US-0371140P.  
PR 09-APR-2002; 2002US-0371185P.  
PR 31-MAY-2002; 2002US-0385089P.  
PR 31-MAY-2002; 2002US-0385426P.  
PR 04-JUN-2002; 2002US-0385751P.  
PR 05-JUN-2002; 2002US-0386018P.  
PR 05-JUN-2002; 2002US-0386367P.  
PR 05-JUN-2002; 2002US-0386548P.  
PR 05-JUN-2002; 2002US-0386553P.  
PR 05-JUN-2002; 2002US-0386566P.  
PR 05-JUN-2002; 2002US-0386577P.  
PR 06-JUN-2002; 2002US-0386283P.  
PR 06-JUN-2002; 2002US-0386390P.  
PR 06-JUN-2002; 2002US-0386430P.  
PR 06-JUN-2002; 2002US-0386601P.  
PR 06-JUN-2002; 2002US-0386826P.  
PR 06-JUN-2002; 2002US-0386869P.  
PR 31-JUL-2002; 2002US-0399972P.  
PR 01-AUG-2002; 2002US-0400348P.  
PR 05-NOV-2002; 2002US-0424053P.  
PR 06-NOV-2002; 2002US-0424380P.  
PR 06-NOV-2002; 2002US-0424395P.  
PR 08-NOV-2002; 2002US-0425086P.  
PR 08-NOV-2002; 2002US-0425200P.  
PR 24-DEC-2002; 2002US-0436243P.  
PR 24-DEC-2002; 2002US-0436288P.  
PR 24-DEC-2002; 2002US-0436345P.

PR 24-DEC-2002; 2002US-0436349P.  
PR 26-DEC-2002; 2002US-0436566P.  
PR 26-DEC-2002; 2002US-0436567P.  
PR 26-DEC-2002; 2002US-0436568P.  
PR 27-DEC-2002; 2002US-0436675P.  
PR 27-DEC-2002; 2002US-0436708P.  
PR 27-DEC-2002; 2002US-0436734P.  
PR 27-DEC-2002; 2002US-0436804P.  
PR 27-DEC-2002; 2002US-0436834P.  
PR 27-DEC-2002; 2002US-0436842P.  
PR 27-DEC-2002; 2002US-0436861P.  
PR 27-DEC-2002; 2002US-0436885P.  
PR 27-DEC-2002; 2002US-0436889P.  
PR 27-DEC-2002; 2002US-0436893P.  
PR 27-DEC-2002; 2002US-0436900P.  
PR 30-DEC-2002; 2002US-0436947P.  
PR 30-DEC-2002; 2002US-0436971P.  
PR 30-DEC-2002; 2002US-0436987P.  
PR 30-DEC-2002; 2002US-0437013P.  
PR 30-DEC-2002; 2002US-0437038P.  
PR 30-DEC-2002; 2002US-0437141P.  
PR 31-DEC-2002; 2002US-0437281P.  
PR 31-DEC-2002; 2002US-0437527P.  
PR 31-DEC-2002; 2002US-0437620P.  
PR 31-DEC-2002; 2002US-0437638P.  
PR 02-APR-2003; 2003WO-CA000462.  
PR 04-APR-2003; 2003WO-CA000464.  
PR 08-APR-2003; 2003WO-CA000481.  
PR 08-APR-2003; 2003WO-CA000485.

XX  
PA (AFFI-) AFFINUM PHARM INC.

XX  
PI Edwards A, Dharamsi A, Vedadi M, Alam MZ, Arrowsmith C, Awrey DE;  
PI Beattie B, Buzadzija K, Canadien V, Domagala M, Houston S;  
PI Kanagarajah D, Li Q, Mansoury K, McDonald M, Nethery-Brokx K, Ng I;  
PI Ouyang H, Pinder B, Richards D, Tai M, Thalakada R, Vallee F;  
PI Virag C;

XX  
DR WPI; 2005-628189/64.  
DR N-PSDB; AEC10796.

XX  
PT New composition comprising purified polypeptides from bacteria (e.g. Escherichia coli), useful for diagnosing, preventing or treating microbial infections, or in pharmacogenomic or drug screening procedures.

XX  
PS Claim 57; SEQ ID NO 329; 667pp; English.

XX  
CC The invention relates to a composition (I) comprising purified polypeptides from bacteria. Also described: (1) a crystallized,

CC recombinant polypeptide comprising an amino acid sequence of (I), where  
CC the polypeptide is in crystal form; (2) a crystallized complex comprising  
CC the crystallized, recombinant polypeptide and a co-factor or a small  
CC organic molecule, where the complex is in crystal form; and (3) a host  
CC cell comprising a nucleic acid encoding a polypeptide of (I), where a  
CC culture of the host cell produces at least about 1 mg of the polypeptide  
CC per liter of culture and the polypeptide is at least about one-third  
CC soluble as measured by gel electrophoresis. The composition and methods  
CC are useful for diagnosing, preventing or treating diseases, such as  
CC microbial infections. These may also be used in pharmacogenomic or drug  
CC screening procedures. The present sequence represents a Enterococcus  
CC faecalis UDP-N-acetylglucosamine pyrophosphorylase protein sequence,  
CC which is used in an example from the present invention.

XX

SQ Sequence 458 AA;

Query Match 78.0%; Score 32; DB 10; Length 458;  
Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
| | | | | | |  
Db 181 LFEALAKT 188

RESULT 14

AAU35344

ID AAU35344 standard; protein; 461 AA.

XX

AC AAU35344;

XX

DT 14-FEB-2002 (first entry)

XX

DE Enterococcus faecalis cellular proliferation protein #631.

XX

KW Antisense; prokaryotic cellular proliferation protein; antibiotic;  
KW antibacterial; drug design.

XX

OS Enterococcus faecalis.

XX

PN WO200170955-A2.

XX

PD 27-SEP-2001.

XX

PF 21-MAR-2001; 2001WO-US009180.

XX

PR 21-MAR-2000; 2000US-0191078P.

PR 23-MAY-2000; 2000US-0206848P.

PR 26-MAY-2000; 2000US-0207727P.

PR 23-OCT-2000; 2000US-0242578P.  
 PR 27-NOV-2000; 2000US-0253625P.  
 PR 22-DEC-2000; 2000US-0257931P.  
 PR 16-FEB-2001; 2001US-0269308P.

XX  
 PA (ELIT-) ELITRA PHARM INC.

XX  
 PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;  
 PI Yamamoto RT, Xu HH;

XX  
 DR WPI; 2001-611495/70.  
 DR N-PSDB; AAS53203.

XX  
 PT New polynucleotides for the identification and development of  
 PT antibiotics, comprise sequences of antisense nucleic acids.

XX  
 PS Example 3; SEQ ID NO 10937; 511pp; English.

XX  
 CC The invention relates to antisense inhibitors of genes essential to  
 CC prokaryotic cellular proliferation, their use in identifying the genes,  
 CC their use in the discovery of novel antibiotics, the essential genes  
 CC themselves and the encoded proteins. The prokaryotes used are Escherichia  
 CC coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae,  
 CC Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also  
 CC useful for the identification of potential new targets for antibiotic  
 CC development. The antisense nucleic acids can also be used to identify  
 CC proteins used in proliferation, to express these proteins, and to obtain  
 CC antibodies capable of binding to the expressed proteins. The proteins can  
 CC be used to screen compounds in rational drug discovery programmes. The  
 CC antisense nucleic acid sequence is also useful to screen for homologous  
 CC nucleic acids which are required for cell proliferation in a wide variety  
 CC of organisms. The present sequence represents an essential prokaryotic  
 CC cellular proliferation protein. Note: The sequence data for this patent  
 CC did not form part of the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC [ftp://wipo.int/pub/published\\_pct\\_sequences](ftp://wipo.int/pub/published_pct_sequences)

XX  
 SQ Sequence 461 AA;

Query Match 78.0%; Score 32; DB 4; Length 461;  
 Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
       |||||||  
 Db 184 LFEALAKT 191

RESULT 15

ADH86988

ID ADH86988 standard; protein; 463 AA.

XX

AC ADH86988;

XX

DT 22-APR-2004 (first entry)

XX

DE Enterococcus faecalis polypeptide #1468.

XX

KW Enterococcus faecalis infection; transcription regulatory element;  
KW antibacterial.

XX

OS Enterococcus faecalis.

XX

PN US6617156-B1.

XX

PD 09-SEP-2003.

XX

PF 13-AUG-1998; 98US-00134000.

XX

PR 15-AUG-1997; 97US-0055778P.

XX

PA (DOUC/) DOUCETTE-STAMM L A.

PA (BUSH/) BUSH D.

XX

PI Doucette-Stamm LA, Bush D;

XX

DR WPI; 2003-895394/82.

DR N-PSDB; ADH83583.

XX

PT New nucleic acid comprising a sequence encoding an Enterococcus faecalis  
PT polypeptide, useful for preparing a composition for diagnosing or  
PT treating E. faecalis infection.

XX

PS Disclosure; SEQ ID NO 4873; 193pp; English.

XX

CC The invention relates to Enterococcus faecalis polynucleotides and  
CC polypeptides. The invention also relates to a recombinant expression  
CC vector comprising a polynucleotide operably linked to a transcription  
CC regulatory element, a cell comprising a recombinant vector, a method for  
CC producing an E. faecalis polypeptide, an isolated nucleic acid comprising  
CC a sequence not given in the specification, a recombinant vector  
CC comprising the nucleic acid and a cell comprising the recombinant vector.  
CC The polynucleotides can be used to detect the presence of E. faecalis in  
CC a sample. The sequences are useful for preparing a composition for  
CC diagnosing or treating Enterococcus faecalis infection. This sequence  
CC represents an E. faecalis polypeptide of the invention.

XX

SQ Sequence 463 AA;

Query Match 78.0%; Score 32; DB 7; Length 463;  
Best Local Similarity 87.5%; Pred. No. 5.5e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
| | | | | | |  
Db 186 LFEALAKT 193

Search completed: June 30, 2008, 17:53:11  
Job time : 77.875 secs